Arrowhead Pharmaceuticals, Inc.: updates and filings

ARWRNASDAQHealthcare · Pharmaceutical Preparations

Price

$43.65

November 19, 2026Market cap $6.2B

What Ploutos Investor adds for Arrowhead Pharmaceuticals

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 16 fiscal years, from FY2011
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Next results

in 77 daysAround Feb 5, 2027 · for Q1 2027

last Nov 12, 2026next Feb 5, 2027

An estimate from when it has reported before, which has been regular. The company announces the date itself.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Nov 12, 2026 latest annualAug 4, 2026 latest quarterly
  • Nov 12, 2026Annual reportfor the period to Sep 30, 2026
    Form10-K
  • Nov 12, 2026Results of operations
    Form8-K
  • Nov 5, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 4, 2026Material agreement entered, new material financial obligation
    Form8-K
  • Aug 14, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Aug 4, 2026Results of operations
    Form8-K
  • Aug 4, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Jul 31, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Jul 27, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Jun 16, 2026Officer or director change
    Form8-K
  • May 19, 2026Filing (amendment)
    Form144/A
  • May 19, 2026Filing (amendment)
    Form144/A
  • May 19, 2026Filing (amendment)
    Form144/A
  • May 7, 2026Shares registered for employees
    FormS-8
  • May 7, 2026Quarterly reportfor the period to Mar 31, 2026
    Form10-Q
  • May 7, 2026Results of operations
    Form8-K
  • May 6, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Apr 29, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Apr 28, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Apr 24, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Mar 26, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Mar 20, 2026Shareholder vote
    Form8-K
  • Feb 5, 2026Quarterly reportfor the period to Dec 31, 2025
    Form10-Q
  • Feb 5, 2026Results of operations
    Form8-K
  • Jan 27, 2026Annual report to shareholdersfor the period to Jan 26, 2026
    FormARS

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jan 2, 1998. Of its note and share prospectuses (424B, FWP), the newest 40 of 44.

The full analysis

What do Arrowhead Pharmaceuticals's filings show?

The filings are where every one of Arrowhead Pharmaceuticals's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.